<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02031861</url>
  </required_header>
  <id_info>
    <org_study_id>CH-004PIV</org_study_id>
    <nct_id>NCT02031861</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension</brief_title>
  <official_title>Random, Open Label, Active Comparator-controlled Parallel Study to Evaluate the Efficacy of Nifedipine Controlled-released Tablets (Xin Ran) in Patients With Mild to Moderate Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Shyndec Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Shyndec Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare nifedipine controlled-release (CR) tablets (Xin Ran)&#xD;
      with nifedipine controlled-release tablets (Adalat）in the treatment of mild to moderate&#xD;
      essential hypertension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in morning blood pressure surge from baseline</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change in central systolic blood pressure, central diastolic blood pressure, central pulse pressure and augmentation index from baseline</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in morning blood pressure from baseline</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T/P ratio</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average reduction in systolic blood pressure from 18 to 24 hours after administration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average reduction in diastolic blood pressure from 18 to 24 hours after administration</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>smoothness index</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in morning blood pressure surge from baseline</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in central systolic blood pressure, central diastolic blood pressure, central pulse pressure and augmentation index from baseline</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in morning blood pressure from baseline</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T/P ratio</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average reduction in systolic blood pressure from 18 to 24 hours after administration</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average reduction in diastolic blood pressure from 18 to 24 hours after administration</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>smoothness index</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in systolic blood pressure (SBP) from baseline</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in diastolic blood pressure (DBP) from baseline</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>clinical laboratory test and adverse event</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>nifedipine CR tablets (Xin Ran)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 12-week treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nifedipine CR tablets (Adalat)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 12-week treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nifedipine CR tablets (Xin Ran)</intervention_name>
    <arm_group_label>nifedipine CR tablets (Xin Ran)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nifedipine CR tablets (Adalat)</intervention_name>
    <arm_group_label>nifedipine CR tablets (Adalat)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntarily participate and must sign informed consent form&#xD;
&#xD;
          -  Mild to moderate essential hypertension (SBP 140-179 mmHg and/or DBP 90-109 mmHg)&#xD;
&#xD;
          -  Average DBP measured by 24-hour ambulatory blood pressure monitoring (ABPM) ≥80 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary hypertension and malignant hypertension&#xD;
&#xD;
          -  Pregnant or nursing women, or patients that cannot guarantee to take effective&#xD;
             contraception measures&#xD;
&#xD;
          -  Baseline SBP≥180 mmHg or DBP≥110 mmHg, or patients with cerebral, cardiac or renal&#xD;
             complications&#xD;
&#xD;
          -  Have following complications: cerebrovascular accident within 6 months, myocardial&#xD;
             infarction or cardiac failure, macroaneurysm or dissecting aneurysm, definite angina,&#xD;
             A-V block of grade 2 or higher, sick sinus syndrome, atrial fibrillation or other&#xD;
             malignant arrhythmia&#xD;
&#xD;
          -  Clinical significant diseases of heart, lung, liver, kidney and hematologic system or&#xD;
             malignant tumors, HIV infection, uncontrolled diabetes (fasting blood glucose ≥7.0&#xD;
             mmol/L, 2-hour postprandial blood glucose ≥7.8 mmol/L)&#xD;
&#xD;
          -  Kock pouch&#xD;
&#xD;
          -  Sever gastrointestinal stenosis&#xD;
&#xD;
          -  Abnormal laboratory values with clinical significance, including serum potassium &lt;3.5&#xD;
             or &gt;5.5 mmol/L, glutamic-pyruvic transaminase (ALT) or glutamic oxalacetic&#xD;
             transaminase (AST) &gt;2-fold upper limit of normal (ULN), Cr &gt;ULN&#xD;
&#xD;
          -  Uric acid &gt;ULN with the diagnosis of gout&#xD;
&#xD;
          -  Gastrointestinal abnormalities or surgery that may interfere with drug absorption&#xD;
&#xD;
          -  Hyperthyroidism or hypothyroidism&#xD;
&#xD;
          -  Allergic to any ingredient or metabolite of investigational drug or drugs of similar&#xD;
             structure&#xD;
&#xD;
          -  Heavy smokers (&gt;25 cigarettes every day), alcoholics (&gt;250 ml liquor every day), drug&#xD;
             addicts&#xD;
&#xD;
          -  Psychological diseases, acrasia, cannot express explicitly&#xD;
&#xD;
          -  Patients whose mood may be affected by variations in blood pressure, which in turn&#xD;
             increases blood pressure&#xD;
&#xD;
          -  Anxiety disorders, depression or cannot follow study protocol&#xD;
&#xD;
          -  BMI &gt;30&#xD;
&#xD;
          -  Night shift, irregular sleep patterns or insomnia&#xD;
&#xD;
          -  participate in other clinical trials within 3 months&#xD;
&#xD;
          -  other conditions that investigators consider unsuitable for participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pingjin Gao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>January 8, 2014</study_first_submitted>
  <study_first_submitted_qc>January 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

